AGN 210676 (Simenepag) (Synonyms: Simenepag) |
| Catalog No.GC31972 |
AGN 210676 (Simenepag) es un agonista selectivo de prostaglandina EP2 extraÍdo de la patente US20070203222A1, Ejemplo de compuesto 23, tiene una EC50 de 5 nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 910562-15-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
AGN 210676 is a selective prostaglandin EP2 agonist extracted from patent US20070203222A1, Compound example 23, has an EC50 of 5 nM.
AGN 210676 (Compound 23) also is a less potent agonist for recombinant human prostaglandin receptors hEP3A and hDP with EC50s of 153 nM and 7749 nM, respectively. AGN 210676 is useful for the treatment of glaucoma, ocular hypertension, inflammatory bowel disease, and the other diseases or conditions disclosed herein[1].
[1]. Old, David W, et al. SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS. US20070203222A1.
Average Rating: 5 (Based on Reviews and 9 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *